Clinical trials: LOCALLY ADVANCED RECTAL CANCER
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Locally Advanced Rectal Adenocarcinoma
Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old
The primary objective of the NACRE-2 trial is to assess whether the addition of chemotherapy after short-course radiotherapy is more effective than short-course radiotherapy alone in elderly patients with locally advanced rectal…
- Trial name
- NACRE-2 (NCT07118800)
- Testing
- FOLFOX4s, Short Course Radiotherapy
- Volunteers
- 160 people
- Sponsor
- UNICANCER
Rectal Cancer
BReak Interval Delayed Surgery for Gastrointestinal Extraperitoneal Rectal Cancer
This is a randomized multicentric clinical trial in patients affected by resectable rectal cancer, cT2N1-2, cT3N0-2, MRF -, aiming to evaluate the impact of the interval between chemoradiotherapy and surgery on the pathological…
- Trial name
- BRIDGE (NCT03581344)
- Testing
- Repetition of Re-staging
- Where
- Italy
- Volunteers
- 148 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Locally Advanced Rectal Cancer
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.
- Trial name
- NCT07469306
- Testing
- Modified Short-course radiotherapy, Long-course radiotherapy, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Rectal Carcinoma
Comparison of the Clinical Response of Total Neoadjuvant Treatment of Two Methods of Long-term or Short-term Chemoradiotherapy in Rectal Cancer
Rectal cancer is one of the most prevalent malignancies in the world, and its prevalence is rising. In more advanced cases neoadjuvant therapy is advised before to surgery, and radiotherapy is one of its cornerstones.
- Trial name
- TEHRAN (NCT05920928)
- Testing
- Short course radiotherapy with concurrent capecitabine(825mg/m2), Long course radiotherapy with concurrent capecitabine(825mg/m2)
- Volunteers
- 114 people
- Sponsor
- Tehran University of Medical Sciences
Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX
Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer
Phase II, Multicenter, Open-label, Randomized Study evaluating neoadjuvant chemotherapy (FOLFOX4) in patients with stage II and III colorectal cancer with standard chemoradiation Defined by Magnetic Resonance Imaging
- Trial name
- RECTUM2015 (NCT05378919)
- Testing
- Radiotherapy 50 Gy, Fluorouracil/folic acid, Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)
- Where
- Lithuania
- Volunteers
- 250 people
- Sponsor
- Lithuanian University of Health Sciences
Colorectal Cancer
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and how telisotuzumab adizutecan moves through the body of adult participants…
- Trial name
- NCT06464692
- Testing
- Telisotuzumab Adizutecan
- Where
- 8 sites in China
- Volunteers
- 31 people
- Sponsor
- AbbVie
Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
This is a phase III, multi-center, double-blind randomized controlled trial assessing the efficacy and safety of concurrent mitomycin C/5-Fu chemotherapy and long-course IMRT combined with PD-1 antibody Sintilimab for locally…
- Conditions
- Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma, Anal Canal Cancer, Anal Cancer
- Trial name
- NCT05374252
- Testing
- PD-1 inhibitor, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer
KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer
This phase II clinical trial is evaluating whether adding KRC-01 injections to standard chemoradiotherapy may improve treatment outcomes in patients with locally advanced rectal cancer without metastases.
- Trial name
- K-BOOST (NCT07622017)
- Testing
- KRC-01 (KORTUC), Radiotherapy, Capecitabine
- Where
- 2 sites in France
- Volunteers
- 24 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Locally Advanced Rectal Cancer
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
phase II clinical trial to evaluate node-sparing short-course radiation combined with total neoadjuvant CAPOX and Sintilimab for MSS locally advanced rectal cancers.
- Trial name
- CASINOs (NCT06204094)
- Testing
- node-sparing short-course radiotherapy, Sintilimab, Capecitabine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Jinhua Central Hospital
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer
Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer
This phase I trial studies the side effects and best dose of fluorouracil when given together with radiation therapy followed by combination chemotherapy before and after surgery in treating patients with rectal cancer that has…
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Rectal Adenocarcinoma
- Trial name
- NCT02270606
- Testing
- intensity-modulated radiation therapy, fluorouracil, oxaliplatin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Virginia Commonwealth University
Metastatic Breast Cancer or Metastatic Colorectal Cancer
A Bioequivalence Study of Capecitabine Tablets
1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG) 2.
- Trial name
- NCT01846650
- Testing
- Capecitabine tablets, XELODA
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Cancer
mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer
The current standard treatment for locally advanced rectal cancer is still fluorouracil-based neoadjuvant radiotherapy and chemotherapy followed by TME surgery, followed by adjuvant chemotherapy.
- Trial name
- FANTASTIC (NCT04338191)
- Testing
- mFOLFOXIRI adjuvant chemotherapy, mFOLFOX6 adjuvant chemotherapy
- Where
- China
- Volunteers
- 638 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Rectal Neoplasms
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.
There is a growing body of evidence that surgery and associated morbidities can be omitted without compromising oncological safety in selected patients who have achieved a clinical complete response after radiochemotherapy.
- Conditions
- Rectal Cancer, Rectal Neoplasms, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- CAO/ARO/AIO-16 (NCT03561142)
- Testing
- Radiotherapy, Chemotherapy, Deep regional hyperthermia
- Where
- 4 sites in Germany
- Volunteers
- 94 people
- Sponsor
- University Hospital Tuebingen
Rectal Cancer
ESD in Locally Advanced Rectal Cancer Following CRT
residual mucosal lesions in patients with locally advanced rectal cancer after CRT are still confusing for decision to continue follow up or excise.
- Trial name
- NCT07192627
- Testing
- Endoscopic mucosal dissection
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Assiut University
Solid Tumor
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Trial name
- NCT06364696
- Testing
- ASP4396
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Rectal Cancer
Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria
Why is this study conducted? The purpose of this study is to improve the treatment efficacy, particularly the pathological complete response rate, in patients with high-risk/extremely high-risk locally advanced rectal cancer…
- Trial name
- STARS-RC10 (NCT07505472)
- Testing
- Experimental Group, Control group
- Where
- China
- Volunteers
- 212 people
- Sponsor
- The First Hospital of Jilin University
Rectal Cancer
Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
Preoperative induction chemotherapy has been successfully used in a variety of malignancies and provides several advantages over postoperative therapy.
- Trial name
- NCT00216086
- Testing
- Capecitabine, Irinotecan, EUS
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gabi Chiorean, MD
Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA)…
- Conditions
- Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Trial name
- ODI-2001-01 (NCT07587827)
- Testing
- Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)
- Where
- 2 sites in France
- Volunteers
- 77 people
- Sponsor
- Centre Georges Francois Leclerc